Five weeks after getting no response from the U.S. | Five weeks after getting no response from the U.S. Department of Health and Human Services on his request for more information on the potential financial impact of Eisai and Biogen’s newly approved Alzheimer’s treatment Leqembi, Sen. Bernie Sanders (I-Vt.) has sent a follow-up letter to the HHS. The drug has been priced at $26,500 per patient per year.
